IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation
© Li et al.; licensee BioMed Central Ltd. 2012
Received: 1 June 2012
Accepted: 5 November 2012
Published: 23 November 2012
IL-1β is a pleiotropic pro-inflammatory cytokine and its up-regulation is closely associated with various cancers including gastrointestinal tumors. However, it remains unclear how IL-1β may contribute to the initiation and development of these inflammation-associated cancers. Here we investigated the role of IL-1β in colon cancer stem cell (CSC) development.
Using self-renewal assay, soft-agar assay, invasion assay, real-time PCR analysis, immunoblot assay and shRNA knockdown, we determined the effects of IL-1β on cancer stem cell development and epithelial-mesenchymal transition (EMT) in human primary colon cancer cells and colon cancer cell line HCT-116.
We found that IL-1β can increase sphere-forming capability of colon cancer cells in serum-free medium. IL-1β-induced spheres displayed an up-regulation of stemness factor genes (Bmi1 and Nestin) and increased drug resistance, hallmarks of CSCs. Importantly, expression of EMT activator Zeb1 was increased in IL-1β-induced spheres, indicating that there might be a close association between EMT and IL-1β-induced CSC self-renewal. Indeed, IL-1β treatment led to EMT of colon cancer cells with loss of E-cadherin, up-regulation of Zeb1, and gain of the mesenchymal phenotype. Furthermore, shRNA-mediated knockdown of Zeb1 in HCT-116 cells reversed IL-1β-induced EMT and stem cell formation.
Our findings indicate that IL-1β may promote colon tumor growth and invasion through activation of CSC self-renewal and EMT, and Zeb1 plays a critical role in these two processes. Thus, IL-1β and Zeb1 might be new therapeutic targets against colon cancer stem cells.
KeywordsColon cancer Tumor microenvironment Inflammation Interleukin-1β Cancer stem cells Epithelial-mesenchymal transition Zeb1
Chronic inflammation is a predisposing cause of various cancers. Interestingly, inflammatory cells and mediators are present in every tumor, including those that are not developed from chronic inflammation [1, 2]. The inflammatory microenvironment around the tumor is a critical component that drives tumor progression, and it is often characterized as the seventh hallmark of cancer . Interleukin-1β (IL-1β) is an important mediator of cancer-related inflammation and can be secreted by immune, stromal and tumor cells . IL-1β levels are increased in a variety of cancers including colon cancer, one of the most common fatal cancers [5, 6]. Recent studies have shown that the interaction between colon cancer cells and immune cells induces secretion of IL-1β from immune cells [7, 8]. Elevated IL-1β levels have been associated with increased colon tumor growth and invasion [9, 10]. However, how IL-1β may contribute to the development of cancer has not been fully explored.
Cancer stem cells (CSCs) are a subpopulation of tumor cells with the ability to undergo self-renewal and recapitulate the entire tumor population in vitro and in vivo. Similar to CSCs from other types of cancers, colon CSCs have been identified from human colon tumor cells using flow cytometry and measuring the expression of stem cell markers [12–14]. The ability to form spheroid cultures in serum-free conditions supplemented with growth factors is also used for identification and expansion of CSCs in vitro[12, 15]. In addition to the capability of self-renewal, CSCs have the ability to initiate distant metastasis to form metastatic growth that resemble the primary tumors, and are resistant to conventional chemotherapy/radiotherapy, implicating that they are responsible for tumor growth and recurrence . Recently, we and others have shown that soluble factors within tumor microenvironment play an important regulatory role in the self-renewal and fate of CSCs [17, 18]. We speculate that IL-1β may promote tumor growth by increasing the self-renewal capability of colon CSCs.
Epithelial-mesenchymal transition (EMT) is a process which involves epithelial cells acquiring a mesenchymal phenotype and migratory capability, and plays an important role in tumor metastasis [19, 20]. EMT can be triggered by various extracellular stimuli and microenvironment factors. The induction of EMT is mediated by a set of key transcription factors within the cell, including Twist, Snail, Snug, Zeb1 and Zeb2, many of which are frequently over-expressed in cancer cells . These EMT activators directly repress the expression of E-cadherin, an integral component of adherens junctions. Importantly, EMT process has been associated with the acquisition of stem cell properties in normal and cancer cells [21, 22]. The link between EMT and CSCs enables cancer cells to migrate from the primary tumor and colonize distant sites.
In this study, we investigated whether IL-1β could promote stem cell and EMT phenotypes in human colon HCT-116 cells as well as in newly established primary colon cancer cells. HCT-116 cells are a well-characterized cellular model of human colon cancer and have been broadly used for colon cancer research. The low passages of freshly isolated human colon cancer cells have allowed us to closely mimic the in vivo state and generate more physiologically relevant data. Here, we provide direct evidence that IL-1β promotes self-renewal of colon cancer cells as well as their acquisition of EMT phenotype, and this induction of CSC and EMT phenotypes was mediated by Zeb1.
Characterization of human primary colon cancer cells
During the first week of culture, all cells freshly isolated from normal mucosa failed to survive, and the majority of cells isolated from colon tumor sections died as well, leaving only a few remaining healthy cells. The initial primary colon cancer cells grew slowly and the culture was maintained for four weeks before they were split for the first passage. Early passages (passage 1–3) of human primary colon cancer (HPCC) cells were used in all experiments in this study.
To assess tumorigenic potential of HPCC cells, we performed a colony-forming assay that is frequently utilized for in vitro evaluation of malignant transformation and tumorigenesis . HPCC cells exhibited transforming capability by forming colonies over the period of two weeks (Figure 1C).
IL-1β promotes sphere formation, expression of stemness markers, and drug resistance
Recent studies suggest that CSCs exhibit intrinsic resistance to conventional chemotherapies . Thus, we evaluated whether IL-1β-promoted HCT-116 sphere cells could display enhanced drug resistance against carboplatin, a conventional chemotherapeutic agent. HCT-116 cells were cultured in serum-free medium with or without IL-1β for five days and then exposed to various concentrations of carboplatin for two days. Cell viability was measured as the percentage of live cells relative to total cell number (dead + live cells). As shown in Figure 3C, IL-1β-treated sphere cells displayed significantly greater resistance to carboplatin at concentrations range from 250 to 1000 μM.
To assess whether IL-1β-induced formation of CSCs was associated with EMT, we examined the expression of EMT activators using real-time PCR and western blot analyses. As shown in Figure 3D and 3E, Zeb1 expression (gene transcript and protein) were augmented in IL-1β-induced HCT-116 and HPCC sphere cells in serum free medium. Interestingly, although the magnitude of induction of Zeb1 mRNA by IL-1β in HPCC cells was markedly greater than that in HCT-116 cells (5.5 fold vs. 1.5 fold, Figure 3D), the difference in Zeb1 protein induction by IL-1β was not that dramatic between HPCC and HCT-116 cells (1.8 fold vs. 1.5 fold, Figure 3E). Nonetheless, this result suggests that Zeb1 may be involved in IL-1β-mediated reactivation or de novo induction of cancer stem cells.
IL-1β induces an EMT phenotype and enhances invasiveness of colon cancer cells
The proliferation status of HCT-116 cells grown under the same conditions was also assessed at the indicated time after plating (Figure 5C). As shown in Figure 5C, IL-1β-treated cells proliferated at the same rates as control cells between 0–36 h time point, but significantly (p < 0.05) more rapidly than control cells after 36 h. This result indicates that enhanced proliferation may have contributed to the faster wound closure of IL-1β-treated culture at late stage, but not during the early-to-mid stage of wound healing.
IL-1β-induced EMT in HCT-116 cells is mediated by Zeb1
To further verify the interaction of Zeb1 and E-cadherin in IL-1β-induced EMT in HCT-116 cells, we first measured the expression of Zeb1 in HCT-116 cells treated with scrambled shRNA or shZeb1. As shown in Figure 6B, Zeb1 protein expression in shZeb1-treated cells was reduced compared to that in HCT-116 cells treated with scramble shRNAs in the absence of IL-1β, and its expression was not increased in the presence of IL-1β. In contrast, Zeb1 expression in HCT-116 cells treated with scrambled shRNA was increased 2.7 fold after IL-1β treatment (Figure 6B, left panel). This clearly indicates that the IL-1β-induced Zeb1 was knocked down effectively. Because the expression of E-cadherin in shZeb1-treated cells did not change in the presence or absence of IL-1β (Figure 6B), our data support the notion that Zeb1 is indeed responsible for IL-β-induced suppression of E-cadherin in HCT-116 cells.
IL-1β-induced CSC self-renewal in HCT-116 cells is mediated by Zeb1 and Bmi-1
To determine the effect of Zeb1 knockdown on self-renewal of HCT-116 cells, scramble and shZeb1 cells were cultured at a very low density (1 cell/μl) in 96-well plates containing serum-free medium with or without IL-1β for seven days. In the absence of IL-1β, Zeb1 knockdown cells showed reduced self-renewal capability by forming smaller sized but similar numbers of spheres compared to scramble cells (Figure 7B & 7C). The reduced self-renewal capability of Zeb1 knockdown cells is comparable to their reduced Bmi-1 expression (Figure 7A). IL-1β treatment led to a significant increase in the number and size of spheres formed from scramble cells, paralleled with their increased Bmi1 expression. As for Zeb1 knockdown cells, IL-1β failed to significantly increase the number of spheres, but the size of these spheres was significantly (p < 0.05) increased (Figure 7B & 7C). The limited effect of Zeb1 knockdown on IL-1β-mediated sphere size increase suggests that in addition to Zeb1, other factors may also contribute to IL-1β-enhanced self-renewal capability. However, the significant inhibition of Zeb1 knockdown on IL-1β-mediated increase of sphere number suggests that Zeb1-Bmi1 pathway is indeed involved in regulation of IL-1β-induced self-renewal.
IL-1β is a pleiotropic cytokine with numerous roles in various physiological and pathological states. Aberrant production and signaling of IL-1β are tightly linked to tumor generation, growth and metastasis in multiple types of cancers [25–29]. Thus far, the exact mechanisms by which IL-1β promotes tumor growth have remained unclear. Using a colon cancer cell line HCT-116 and primary colon cancer cells, we have found that IL-1β can promote sphere-forming capacity concomitant with up-regulated expression of stemness markers Bmi1 and nestin in colon cancer cells, suggesting that IL-1β increases the self-renewal of colon CSCs. In addition, IL-1β-induced spheres display augmented drug resistance, a property associated with CSCs. Importantly, IL-1β induces cellular morphological changes in colon cancer cells that are consistent with the acquisition of EMT phenotype as characterized by the loss of E-cadherin expression. Furthermore, IL-1β-induced EMT cells display enhanced migratory capacity compared with parental cells with an epithelial phenotype. Overall, our studies provide the first evidence that IL-β promotes CSC self-renewal and EMT in colon cancer cells, which may contribute to colon cancer growth, metastasis and recurrence.
Bmi-1 is a transcriptional repressor belonging to the polycomb group protein family, which functions in gene silencing through chromatin modification [30, 31]. Bmi-1 plays a crucial role in the self-renewal of normal and neoplastic stem cells [32–37]. In addition to Bmi-1, several other molecules have been proposed as colon CSC markers including CD133, CD44, Lgr-5 and pluripotency genes such as Oct-4, Sox-2 and Nanog . However, recent studies by others have shown that NANK, a human colon tumor cell line with a high level of Bmi-1 expression but negative for CD133, CD44, Oct4, and Nanog, is capable of initiating tumors in mice . This report suggests that Bmi-1 is crucial for the self-renewal and oncogenic potential of colon CSCs. In addition, aberrant expression of Bmi-1 has been reported in human colon cancer and its expression levels correlate with clinical and pathological stages of colon malignancies, further assuring the oncogenic role of Bmi-1 in colon cancer [40–42]. Here we have found that the enhanced sphere formation and proliferation in HCT-116 and HPCC cells treated with IL-1β are associated with significantly augmented Bmi-1 expression in these cells. This observation supports the notion that IL-1β acts through Bmi-1 to promote the self-renewal and proliferation of colon cancer stem cells.
Zeb1, Zeb2 and transcription factors such as Snail, Slug, E47 and Twist are all able to activate EMT through binding to the E-cadherin promoter and repressing its transcription . In this study, we found that the expression of Zeb1, but not Zeb2, Snail or Twist, was up-regulated in IL-1β-induced HCT-116 and HPCC EMT cells. This indicates that IL-1β may act through Zeb1 to induce EMT in colon cancer cells. The importance of Zeb1 in IL-1β-induced EMT in colon cancer cells is further highlighted in Zeb1 knockdown HCT-116 cells, which display a close association between the lack of EMT and the disappearance of IL-1β-induced repression of E-cadherin transcription in these cells (Figure 6). Interestingly, IL-1β-induced Zeb1 expression has also been observed in head and neck squamous carcinoma cells . Thus, Zeb1 may play a key role in IL-1β-induced EMT in various cancer cells.
It has been reported that Zeb1 links the EMT process and acquisition of CSC properties through a double-negative feedback loop with microRNA-200, a repressor of Bmi1 expression [45–48]. Our results show that Zeb1 was also up-regulated along with Bmi1 in IL-1β-induced HCT-116 and HPCC spheres. Thus, the parallel up-regulation of Zeb1 and Bmi1 by IL-1β suggests that IL-β-induced self-renewal of colon cancer cells may involve the Zeb1-Bmi1 pathway. This notion is supported by the behavior of Zeb1 knockdown HCT-116 cells, in which Bmi1 expression is reduced in the absence of IL-1β and its expression is not increased in the presence of IL-1β, compared to that in control cells (Figure 7A). In addition, Zeb1 knockdown cells displayed reduced self-renewal capacity in the absence or presence of IL-1β, compared to that of control cells (Figure 7B).
Although our data support the hypothesis that Zeb1-Bmi1 pathway is critical for IL-β-induced self-renewal of colon CSCs, we cannot rule out the possibility that other stemness factors are also involved in IL-β-induced self-renewal. This is because Zeb1 knockdown cells still demonstrate obvious increases in the self-renewal capacity after IL-β treatment. Thus, we speculate that IL-1β enhances self-renewal of colon CSCs through activating a multifaceted stemness system in which the Zeb1-Bmi1 pathway is a part of an essential network.
EMT enables tumor metastasis and CSC self-renewal is a key driving force for tumor growth and recurrence after chemotherapy. IL-1β is a major pro-inflammatory cytokine that has been closely linked to enhanced growth and invasion of colon cancer. Using a colon cancer cell line and primary colon cancer cells, we have demonstrated that IL-1β may act via Zeb1 to promote EMT and stem cell development in colon cancer cells, which may contribute to colon tumor malignancy. Thus, IL-1β and Zeb1 can be potential therapeutic targets aimed at cancer stem cells in the development of novel treatments for colon cancer.
Isolation of primary colon cancer cells and cell culture
Tumor samples and corresponding normal mucosa from a patient with stage 2 colon cancer were obtained from the Surgical Associates, Manhattan, KS. The proposal (#5753) to isolate human colon cancer cells was reviewed and approved by the Institutional Review Board (IRB) for Kansas State University. At operation, collected tissues were placed in McCoy’s 5A Medium with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (Invitrogen Corp, Carlsbad, CA) on ice and transported to the laboratory immediately. The fresh tissue was cut into small pieces (1 mm) using scissors and digested with 3 ml (0.4 mg/ml) Collagenase A (Roche Applied Science, Indianapolis, IN) at 37°C for 1 h with interval agitation. Twenty microliter of EDTA (500 mM) was used to stop the reaction. The dispersed tissues were quickly mixed in a homogenizer and the mixture was filtered through a 70 μm strainer (BD Falcon, San Jose, CA) to remove tissue fragments. Cells were washed with PBS, spun down by centrifugation and cultured in McCoy’s 5A Medium with 10% FBS and 1% penicillin-streptomycin in a humidified incubator with 37°C and 5% CO2.
Human colon cancer cell line HCT-116 was obtained from the American Type Culture Collection (Manassas, VA) and maintained in McCoy’s 5A Medium with 10% FBS and 1% penicillin-streptomycin. To induce EMT, HCT-116 cells and primary colon cancer cells HPCC were cultured in McCoy’s 5A Medium with 1% FBS in the presence 200 pM IL-1β (R&D Systems, Minneapolis, MN) for seven days. To induce sphere formation, cells were cultured in serum-free medium (SFM) which consisted of neurobasal-A medium supplemented with B27, GlutaMAX-I supplement, 1% penicillin-streptomycin (all from Invitrogen Corp), 50 ng/ml heparin (Sigma-Aldrich, Saint Louis, MO), 20 ng/ml of EGF, and 20 ng/ml bFGF (R&D systems, Minneapolis, MN). To determine the effect of IL-1β, 200 pM IL-1β was added to the serum-free medium every other day.
Primary colon cancer cells were seeded in slide chambers (Fisher Scientific, Hanover Park, IL) and cultured for seven days in McCoy’s 5A Medium with 10% FBS. Then, cells were fixed with 4% paraformaldehyde, permeablized with PBS containing 0.5% Triton X-100, and incubated with pan-cytokeratin (C 2562, Sigma) or vimentin (sc-6260, Santa Cruz Biotechnology, Santa Cruz, CA) mouse monoclonal antibodies, and followed by secondary chicken anti-mouse IgG (H + L) antibody conjugated with Alexa 488 (Invitrogen). Cells were then mounted with VECTASHIELD Mounting Medium with DAPI (Vector laboratories, Burlingame, CA) and observed with a confocal microscope.
Soft agar colony formation assay
Anchorage independent growth in soft agar was used to determine the transformation and growth of the primary colon cancer cells in vitro. The soft agar assay was performed in 6-well plates containing two layers of Sea Plague Agar (Invitrogen). The bottom layer consisted of 0.8% agar in 1 ml of McCoy’s 5A Medium with 10% FBS. The primary colon cancer cells (1x104/well) were placed in the top layer containing 0.4% agar in the same medium as the bottom. Cells were cultured for 14 days and colonies were photographed under a microscope.
Control monolayer and IL-1β-induced sphere cells in serum-free medium were treated with carboplatin (Sigma-Aldrich) at concentrations of 250, 500, 1000 μM for two days. Then cells were stained with Trypan blue (Amresco Inc., Solon, OH) and counted under a microscope. The viability of the cells was measured as the percentage of live cells over the total of live and dead cells.
Wound healing assay
HCT-116 cells were cultured for four days in 6-well plates containing McCoy’s 5A Medium plus 10% serum to generate a confluent monolayer. The media was then removed and two wounds per well were made by scraping with pipette tips. The wounds were examined to ensure that the cells were removed completely. The plates were washed twice with PBS to remove cellular debris and then McCoy’s 5A Medium with 1% serum with or without IL-1β was added. Pictures from the same area of the wound were taken under a microscope at 0, 12, 24 and 48 h after scraping. For each wound, the distance of the gap was the average of four fields. The measurement for six wounds per treatment were collected and analyzed statistically.
Self-renewal assay and cell proliferation assay
HCT-116 cells (1 cell/μl in SFM) and primary colon cancer cells (1 cell/μl in SFM) were seeded at 100 μl/well in 96-well plates and treated with or without 200 pM IL-1β for seven days. IL-1β was added every other day. The total number of spheres in each well was counted under a microscope. Then cells were dissociated, stained with Trypan blue (Amresco Inc., Solon, OH) and counted under a microscope to determine the total cell number.
RNA extraction and real-time PCR
Total RNA was extracted using TRI reagent (Sigma-Aldrich), followed by digestion with a DNase kit (Applied Biosystems, Carlsbad, California) to remove DNA residues. Reverse transcription was carried out using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) and quantitative real-time PCR was performed using SsoFast Eva Green Supermix kit (Bio-Rad). β-actin was used as an internal normalization control.
HCT-116 cells and primary colon cancer cells were cultured in McCoy’s 5A Medium with 1% FBS or in serum-free medium in the absence or presence of IL-1β for seven days. Cells were then washed with cold PBS, lysed in RIPA buffer [25 mM Tris–HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) and pelleted by centrifugation. Protein concentrations were determined using a NanoDrop instrument (Thermo Scientific, Wilmington, DE). Cell lysates (30 μg protein for each sample) were incubated for 5 min at 1000C in 2x loading buffer, separated by electrophoresis in 10% polyacrylamide gels, and transferred to PVDF membranes (Millipore, Bedford, MA). Membranes were blocked with 5% milk in TBST and then incubated with primary antibodies. The anti-Zeb1, anti-Nestin and anti-Bmi1 (H99) antibodies were from Santa Cruz biotechnology (Santa Cruz, CA). The anti-E-cadherin and anti-Bmi1 clone F6 antibodies were from Millipore and anti-β-actin antibody was from Sigma. After washing with TBST, the membrane was incubated with one of the two secondary antibodies, HRP-conjugated goat anti-mouse IgG-HRP (Millipore) or anti-rabbit IgG HRP-linked antibody (Cell Signaling, Danvers, MA). Detection was performed using HyGLO substrate (Denville Scientific, Metuchen, NJ) and images were taken using an AlphaEaseFC imaging system (Cell biosciences, Santa Clara, CA). The graph digitizing software UN-SCAN-IT (Silk Scientific, Orem, Utah) was used to quantify intensities of protein bands.
Infection with shRNA lentiviral particles
HCT-116 cells were cultured in McCoy’s 5A Medium with 10% FBS until they became 50% confluent. Then cells were infected with scrambled or Zeb1 shRNA lentiviral particles (Santa Cruz) as described by the manufacturer. Stable infected cells were established via selection with puromycin (10 μg/ml).
Student’s t test was used to determine statistical significance for all analyzed data. We consider a two-sided p < 0.05 as significant.
We thank Joel Sanneman and Don Harbidge for their technical support. This research was supported in part by Innovative Research Award (L. Wang) from Johnson Center for Basic Cancer Research at Kansas State University, NIH R21 AI085416 (J. Shi), KBA-CBRI 611310 (J. Shi), NIH NCRR P20-RR017686 (PI: Daniel Marcus; J. Shi). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Oshima M, Taketo MM: COX selectivity and animal models for colon cancer. Curr Pharm Des. 2002, 8: 1021-1034. 10.2174/1381612023394953View ArticlePubMed
- Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454: 436-444. 10.1038/nature07205View ArticlePubMed
- Mantovani A: Cancer: Inflaming metastasis. Nature. 2009, 457: 36-37.View ArticlePubMed
- Germano G, Allavena P, Mantovani A: Cytokines as a key component of cancer-related inflammation. Cytokine. 2008, 43: 374-379. 10.1016/j.cyto.2008.07.014View ArticlePubMed
- Apte RN, Voronov E: Interleukin-1–a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol. 2002, 12: 277-290. 10.1016/S1044-579X(02)00014-7View ArticlePubMed
- Colasante A, Mascetra N, Brunetti M, Lattanzio G, Diodoro M, Caltagirone S, Musiani P, Aiello FB: Transforming growth factor beta 1, interleukin-8 and interleukin-1, in non-small-cell lung tumors. Am J Respir Crit Care Med. 1997, 156: 968-973.View ArticlePubMed
- Bessler H, Djaldetti M: Role of the equilibrium between colon cancer and mononuclear cells in cytokine production. Biomed Pharmacother. 2010, 64: 706-711. 10.1016/j.biopha.2010.08.006View ArticlePubMed
- Kaler P, Godasi BN, Augenlicht L, Klampfer L: The NF-kappaB/AKT-dependent Induction of Wnt Signaling in Colon Cancer Cells by Macrophages and IL-1beta. Cancer Microenviron. 2009, 2: 69-80. 10.1007/s12307-009-0030-y.PubMed CentralView ArticlePubMed
- Jedinak A, Dudhgaonkar S, Sliva D: Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology. 2010, 215: 242-249. 10.1016/j.imbio.2009.03.004View ArticlePubMed
- Kaler P, Augenlicht L, Klampfer L: Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene. 2009, 28: 3892-3902. 10.1038/onc.2009.247PubMed CentralView ArticlePubMed
- Jordan CT: Cancer stem cells: controversial or just misunderstood?. Cell Stem Cell. 2009, 4: 203-205. 10.1016/j.stem.2009.02.003PubMed CentralView ArticlePubMed
- Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature. 2007, 445: 111-115. 10.1038/nature05384View ArticlePubMed
- Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007, 104: 10158-10163. 10.1073/pnas.0703478104PubMed CentralView ArticlePubMed
- O’Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007, 445: 106-110. 10.1038/nature05372View ArticlePubMed
- Dontu G, Wicha MS: Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia. 2005, 10: 75-86. 10.1007/s10911-005-2542-5View ArticlePubMed
- Boman BM, Huang E: Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol. 2008, 26: 2828-2838. 10.1200/JCO.2008.17.6941View ArticlePubMed
- Castano Z, Fillmore CM, Kim CF, McAllister SS: The bed and the bugs: Interactions between the tumor microenvironment and cancer stem cells. Semin Cancer Biol. 2012, In press.
- Wang L, Liu Z, Balivada S, Shrestha T, Bossmann S, Pyle M, Pappan L, Shi J, Troyer D: Interleukin-1beta and transforming growth factor-beta cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells. Stem Cell Res Ther. 2012, 3: 5- 10.1186/scrt96PubMed CentralView ArticlePubMed
- Biddle A, Mackenzie IC: Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev. 2012, In press.
- Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139: 871-890. 10.1016/j.cell.2009.11.007View ArticlePubMed
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027PubMed CentralView ArticlePubMed
- May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA: Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res. 2011, 13: 202-PubMed CentralView ArticlePubMed
- Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, Garcia-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J: TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009, 15: 315-327. 10.1016/j.ccr.2009.02.011View ArticlePubMed
- Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH: Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat. 2010, 13: 109-118. 10.1016/j.drup.2010.07.001PubMed CentralView ArticlePubMed
- Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG, Wang TC: Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008, 14: 408-419. 10.1016/j.ccr.2008.10.011PubMed CentralView ArticlePubMed
- Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M: C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci. 2004, 49: 970-976.View ArticlePubMed
- Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, Apte RN: Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007, 67: 1062-1071. 10.1158/0008-5472.CAN-06-2956View ArticlePubMed
- Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN: IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003, 100: 2645-2650. 10.1073/pnas.0437939100PubMed CentralView ArticlePubMed
- Kaler P, Galea V, Augenlicht L, Klampfer L: Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells. PLoS One. 2010, 5: e11700- 10.1371/journal.pone.0011700PubMed CentralView ArticlePubMed
- Park IK, Morrison SJ, Clarke MF: Bmi1, stem cells, and senescence regulation. J Clin Invest. 2004, 113: 175-179.PubMed CentralView ArticlePubMed
- Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M: Stem cells and cancer; the polycomb connection. Cell. 2004, 118: 409-418. 10.1016/j.cell.2004.08.005View ArticlePubMed
- Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, Clarke MF: Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003, 423: 302-305. 10.1038/nature01587View ArticlePubMed
- Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ: Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature. 2003, 425: 962-967. 10.1038/nature02060PubMed CentralView ArticlePubMed
- Sangiorgi E, Capecchi MR: Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet. 2008, 40: 915-920. 10.1038/ng.165PubMed CentralView ArticlePubMed
- Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD, de Sauvage FJ: A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature. 2011, 478: 255-259. 10.1038/nature10408PubMed CentralView ArticlePubMed
- Grinstein E, Wernet P: Cellular signaling in normal and cancerous stem cells. Cell Signal. 2007, 19: 2428-2433. 10.1016/j.cellsig.2007.06.021View ArticlePubMed
- Facchino S, Abdouh M, Chatoo W, Bernier G: BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci. 2010, 30: 10096-10111. 10.1523/JNEUROSCI.1634-10.2010View ArticlePubMed
- Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG: Colorectal cancer stem cells. Stem Cells. 2012, 30: 363-371. 10.1002/stem.1031View ArticlePubMed
- Navarro-Alvarez N, Kondo E, Kawamoto H, Hassan W, Yuasa T, Kubota Y, Seita M, Nakahara H, Hayashi T, Nishikawa Y, Hassan RA, Javed SM, Noguchi H, Matsumoto S, Nakaji S, Tanaka N, Kobayashi N, Soto-Gutierrez A: Isolation and propagation of a human CD133(−) colon tumor-derived cell line with tumorigenic and angiogenic properties. Cell Transplant. 2010, 19: 865-877. 10.3727/096368910X508997PubMed CentralView ArticlePubMed
- Siddique HR, Saleem M: Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells. 2012, 30: 372-378. 10.1002/stem.1035View ArticlePubMed
- Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ, Li SX, Wang XL, Peng ZH: Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol. 2010, 136: 997-1006. 10.1007/s00432-009-0745-7View ArticlePubMed
- Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW: The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 2004, 203: 217-224. 10.1016/j.canlet.2003.07.009View ArticlePubMed
- Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007, 7: 415-428. 10.1038/nrc2131View ArticlePubMed
- Dohadwala M, Wang G, Heinrich E, Luo J, Lau O, Shih H, Munaim Q, Lee G, Hong L, Lai C, Abemayor E, Fishbein MC, Elashoff DA, Dubinett SM, St John MA: The role of ZEB1 in the inflammation-induced promotion of EMT in HNSCC. Otolaryngol Head Neck Surg. 2010, 142: 753-759. 10.1016/j.otohns.2010.01.034View ArticlePubMed
- Brabletz S, Brabletz T: The ZEB/miR-200 feedback loop–a motor of cellular plasticity in development and cancer?. EMBO Rep. 2010, 11: 670-677. 10.1038/embor.2010.117PubMed CentralView ArticlePubMed
- Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K, Clarke MF: Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009, 138: 592-603. 10.1016/j.cell.2009.07.011PubMed CentralView ArticlePubMed
- Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu Q, Song E, Li J: MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene. 2012, 31: 432-445. 10.1038/onc.2011.263View ArticlePubMed
- Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, Zur Hausen A, Brunton VG, Morton J, Sansom O, Schuler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T: The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009, 11: 1487-1495. 10.1038/ncb1998View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.